Meeting
2021 ASCO Annual Meeting
Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.
Authors
Matthew J. Matasar
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Matthew J. Matasar , Marcelo Capra , Muhit Özcan , Fangfang Lv , Wei Li , Eduardo Yanez , Katya Sapunarova , Tongyu Lin , Jie Jin , Wojciech Jurczak , Aryan Hamed , Ming-Chung Wang , Lidia Mongay Soler , Anjun Cao , Charles Phelps , Barrett H. Childs , Yuankai Shi , Pier Luigi Zinzani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02367040
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7510)
DOI
10.1200/JCO.2021.39.15_suppl.7510
Abstract #
7510
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
First Author: Laurie Helen Sehn
Poster
2015 ASCO Annual Meeting
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
First Author: Nathan Hale Fowler
Poster
2014 ASCO Annual Meeting
A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
First Author: Nathan Hale Fowler
Poster
2024 ASCO Annual Meeting
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
First Author: Umberto Vitolo